Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014 Read more about Agios Pharmaceuticals to Present Clinical Data from AG-120 Ongoing Phase 1 Study in Hematologic Malignancies at EORTC-NCI-AACR 2014
Agios Pharmaceuticals to Present at the 2014 Leerink Partners Rare Disease Roundtable Read more about Agios Pharmaceuticals to Present at the 2014 Leerink Partners Rare Disease Roundtable
Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation Read more about Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation
Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results Read more about Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results
Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014 Read more about Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014
Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia Read more about Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia
New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies Read more about New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies
Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration Read more about Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration
Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia Read more about Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia
Agios Pharmaceuticals to Present at the Goldman Sachs 35th Annual Global Healthcare Conference Read more about Agios Pharmaceuticals to Present at the Goldman Sachs 35th Annual Global Healthcare Conference